| Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
| Tel: |
18818260767 |
| Email: |
sales@chemegen.com |
| Products Intro: |
Product Name:ND-336
CAS:1807453-83-3
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
| Company Name: |
MedBioPharmaceutical Technology Inc
|
| Tel: |
021-69568360 18916172912 |
| Email: |
order@med-bio.cn |
| Products Intro: |
Product Name:ND-336
CAS:1807453-83-3
Purity:98% Package:1mg; 5mg; 500ug; 10mg Remarks:Medbio
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:ND-336
CAS:1807453-83-3
Package:10mg/RMB 10500;1mg/RMB 1470;5mg/RMB 5960
|
ND-336 manufacturers
- ND-336
-
- $1500.00 / 10mg
-
2024-10-24
- CAS:1807453-83-3
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| Product Name: | ND-336 | | Synonyms: | ND-336;ND-336 hydrochloride;4-[4-[(2-thiiranylmethyl)sulfonyl]phenoxy]-benzenemethanamine,monohydrochloride | | CAS: | 1807453-83-3 | | MF: | C16H18ClNO3S2 | | MW: | 371.89 | | EINECS: | | | Product Categories: | | | Mol File: | 1807453-83-3.mol |  |
| | ND-336 Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMF: 5 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2)(1:5): 0.16 mg/ml | | form | A crystalline solid | | color | White to off-white |
| | ND-336 Usage And Synthesis |
| Description | ND-336 is a novel highly selective inhibitor of gelatinases (MMP-2 and MMP-9) and MMP-14. ND-336 accelerates diabetic wound healing by lowering inflammation and by enhancing angiogenesis and re-epithelialization of the wound, thereby reversing the pathological condition. ND-336 holds considerable promise in healing of diabetic wounds. | | Uses | ND-336 is a selective inhibitor of matrix metalloproteinase (MMP)-2, MMP-9, and MMP-14, with Kis of 85, 150, and 120 nM, respectively. ND-336 accelerates diabetic wound healing in mice by lowering inflammation and by enhancing angiogenesis and re-epithelialization of the wound[1][2]. | | in vivo | ND-336 accelerates diabetic wound healing by decreasing inflammation and by enhancing angiogenesis and re-epithelialization of the wound, thus reversing the pathological condition[1].
ND-336 (0.05-0.01 mg; topical application; daily for 14 day) accelerates diabetic wound healing[1]. | Animal Model: | Female diabetic db/db mice[1] | | Dosage: | 0.05, 0.025, and 0.01 mg | | Administration: | Topical application; daily for 14 day | | Result: | Healed 1.2- to 1.6-fold faster than those treated with ND-322 than those treated with vehicle.
|
| | IC 50 | MMP-2: 85 nM (Ki); MMP-9: 150 nM (Ki); MMP-14: 120 nM (Ki) | | References | [1] Gao M, et al. Acceleration of diabetic wound healing using a novel protease-anti-protease combination therapy. Proc Natl Acad Sci U S A. 2015;112(49):15226-15231. DOI:10.1073/pnas.1517847112
[2] Nguyen TT, et al. Validation of Matrix Metalloproteinase-9 (MMP-9) as a Novel Target for Treatment of Diabetic Foot Ulcers in Humans and Discovery of a Potent and Selective Small-Molecule MMP-9 Inhibitor That Accelerates Healing. J Med Chem. 2018;61(19):8825-8837. DOI:10.1021/acs.jmedchem.8b01005 |
| | ND-336 Preparation Products And Raw materials |
|